StockData
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. (WHWK) stock

WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.13+0.05 (+1.62%)

Close on Nov 18, 2026Market cap $178.44MP/E –Yield –

Whitehawk Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Whitehawk Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$69.35M. For fiscal 2025 it was -$97.43M. The highest annual figure on record is -$16.02K in fiscal 2014.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$97.43M–
FY2024Dec 31, 2024-$59.55M–
FY2023Dec 31, 2023-$59.66M–
FY2022Dec 31, 2022-$49.64M–
FY2021Dec 31, 2021-$22.42M–
FY2020Dec 31, 2020-$12.70M–
FY2019Dec 31, 2019-$23.85M–
FY2018Dec 31, 2018-$5.81M–
FY2017Dec 31, 2017-$18.88M–
FY2016Dec 31, 2016-$15.72M–
FY2015Dec 31, 2015-$21.73K–
FY2014Dec 31, 2014-$16.02K–
FY2013Dec 31, 2013-$23.32K–
FY2012Dec 31, 2012-$24.52K–
FY2011Dec 31, 2011-$22.77K–
FY2010Dec 31, 2010-$19.24K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$14.53M–
Q1 FY2026Mar 31, 2026-$22.21M–
Q4 FY2025Dec 31, 2025-$17.23M–
Q3 FY2025Sep 30, 2025-$15.38M–
Q2 FY2025Jun 30, 2025-$52.96M–
Q1 FY2025Mar 31, 2025-$11.86M–
Q4 FY2024Dec 31, 2024-$15.05M–
Q3 FY2024Sep 30, 2024-$15.69M–
Q2 FY2024Jun 30, 2024-$9.16M–
Q1 FY2024Mar 31, 2024-$19.65M–
Q4 FY2023Dec 31, 2023-$9.64M–
Q3 FY2023Sep 30, 2023-$11.95M–
Q2 FY2023Jun 30, 2023-$16.76M–
Q1 FY2023Mar 31, 2023-$21.31M–
Q4 FY2022Dec 31, 2022-$11.31M–
Q3 FY2022Sep 30, 2022-$8.20M–
Q2 FY2022Jun 30, 2022-$10.72M–
Q1 FY2022Mar 31, 2022-$19.42M-283.8%
Q4 FY2021Dec 31, 2021-$12.43M–
Q3 FY2021Sep 30, 2021-$17.37M–
Q2 FY2021Jun 30, 2021-$3.19M-130.9%
Q1 FY2021Mar 31, 2021$10.56M–
Q4 FY2020Dec 31, 2020-$3.28M–
Q3 FY2020Sep 30, 2020-$15.78M–
Q2 FY2020Jun 30, 2020$10.29M–
Q1 FY2020Mar 31, 2020-$3.94M–
Q4 FY2019Dec 31, 2019-$4.87M–
Q3 FY2019Sep 30, 2019-$4.76M–
Q2 FY2019Jun 30, 2019-$5.15M-139.2%
Q1 FY2019Mar 31, 2019-$9.08M–
Q4 FY2018Dec 31, 2018-$6.18M–
Q3 FY2018Sep 30, 2018-$6.22M–
Q2 FY2018Jun 30, 2018$13.11M–
Q1 FY2018Mar 31, 2018-$6.51M–
Q4 FY2017Dec 31, 2017-$4.61M–
Q3 FY2017Sep 30, 2017-$4.02M–
Q2 FY2017Jun 30, 2017-$6.32M–
Q1 FY2017Mar 31, 2017-$3.93M–
Q4 FY2016Dec 31, 2016-$3.04M–
Q3 FY2016Sep 30, 2016-$4.83M–

More Whitehawk Therapeutics figures

See a number that looks wrong?